+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia



Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia



European Journal of Haematology 83(2): 90-98



Acute myeloid leukemia (AML) has been thought to be the consequence of two broad complementation classes of mutations: class I and class II. However, overlap-mutations between them or within the same class and the position of TP53 mutation are not fully analyzed. We comprehensively analyzed the FLT3, cKIT, N-RAS, C/EBPA, AML1, MLL, NPM1, and TP53 mutations in 144 newly diagnosed de novo AML. We found 103 of 165 identified mutations were overlapped with other mutations, and most overlap-mutations consisted of class I and class II mutations. Although overlap-mutations within the same class were found in seven patients, five of them additionally had the other class mutation. These results suggest that most overlap-mutations within the same class might be the consequence of acquiring an additional mutation after the completion both of class I and class II mutations. However, mutated genes overlapped with the same class were limited in N-RAS, TP53, MLL-PTD, and NPM1, suggesting the possibility that these irregular overlap-mutations might cooperatively participate in the development of AML. Notably, TP53 mutation was overlapped with both class I and class II mutations, and associated with morphologic multilineage dysplasia and complex karyotype. The genotype consisting of complex karyotype and TP53 mutation was an unfavorable prognostic factor in entire AML patients, indicating this genotype generates a disease entity in de novo AML. These results collectively suggest that TP53 mutation might be a functionally distinguishable class of mutation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269753

Download citation: RISBibTeXText

PMID: 19309322

DOI: 10.1111/j.1600-0609.2009.01261.x


Related references

Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. Leukemia & Lymphoma 53(11): 2214-2217, 2013

NF1 gene deletions and mutations in de novo adult acute myeloid leukemia. 2013

Expression of HLA Class I and Class II antigens on the surface of leukemic blasts in acute myeloid leukemia. Blood 94(10 SUPPL 1 PART 1): 504a, Nov 15, 1999

Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. European Journal of Haematology 65(1): 23-31, July, 2000

Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. American Journal of Hematology 88(4): 306-311, 2013

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 28(14): 2348-2355, 2010

A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia. Leukemia & Lymphoma 53(6): 1230-1233, 2012

Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases from the Cancer Genome Atlas (TCGA) with 23 Most Common Mutations and no Abnormal Cytogenetics. Annals of Clinical and Laboratory Science 45(5): 515-521, 2016

The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell. Experimental Hematology 42(11): 955-65.E1-5, 2015

ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia. Leukemia & Lymphoma 56(6): 1881-1883, 2016

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 28(4): 596-604, 2010

CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese population. Oncotargets and Therapy 9(): 3399-3403, 2016

Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia. Leukemia & Lymphoma 55(2): 349-357, 2014

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 114(26): 5352-5361, 2010

Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia. International Journal of Oncology 12(6): 1259-1262, 1998